Anastrozole recommended for prevention of breast cancer
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - November 30, 2016 Category: Drugs & Pharmacology Source Type: news

Older DCIS Patients Have Low Rates of Tamoxifen, AI Usage
The initiation of and adherence to tamoxifen or aromatase inhibitors (AIs) such as anastrozole is low among older women with estrogen receptor-positive ductal carcinoma in situ. (Source: CancerNetwork)
Source: CancerNetwork - November 1, 2016 Category: Cancer & Oncology Authors: Dave Levitan Tags: Breast Cancer News Source Type: news

ASCO: Clinical and QOL Benefits With Arimidex in Endometrial Ca (CME/CE)
(MedPage Today) -- 44% clinical benefit rate, median PFS of 3.2 months in recurrent disease (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - June 15, 2016 Category: Hematology Source Type: news

AstraZeneca finds faslodex better than arimidex in treating metastatic breast cancer
AstraZeneca has found that faslodex 500mg (fulvestrant) is demonstrating better results than arimidex 1mg (anastrozole) while treating locally-advanced or metastatic breast cancer in post-menopausal women, who have not had prior hormonal treatment fo… (Source: Drug Development Technology)
Source: Drug Development Technology - May 30, 2016 Category: Pharmaceuticals Source Type: news

Which Medication is More Cost Effective?
Tamoxifen and Arimidex are two hormone therapy drugs that are commonly prescribed to prevent recurrence of hormone-sensitive breast cancer. (Source: About.com Breast Cancer)
Source: About.com Breast Cancer - February 15, 2016 Category: Cancer & Oncology Authors: breastcancer.guide at about.com Tags: health Source Type: news

Prioritizing Patients Over Profits
Imagine a pharmaceutical company that distributes all profits to patient support and medical research... Enter For Benefit Medicines (FBM), established by Dr Barry Frost, in partnership with John Hurley. Frost holds a PhD in pharmacology and has spent 35 years working for four different major pharmaceutical companies. With a rich and varied experience in pharma, it has been the ‘for benefit’ model that has interested him most over the past few years. After reading an article in the Harvard Business Review (November 2011 edition) entitled “The For Benefit Enterprise,” Frost was intrigued by the documented case stu...
Source: EyeForPharma - January 25, 2016 Category: Pharmaceuticals Authors: Dr Nicola Davies Source Type: news

Drug Trials in DCIS Almost a Wash (CME/CE)
(MedPage Today) -- Patient preference in side effects likely to influence choice of Arimidex or Nolvadex (Source: MedPage Today Meeting Coverage)
Source: MedPage Today Meeting Coverage - December 14, 2015 Category: Journals (General) Source Type: news

Two Drugs Equal in Preventing Early Breast Cancer's Return: Study
Women with ductal carcinoma in situ had similar outcomes with tamoxifen, anastrozole (Source: Cancercompass News: Breast Cancer)
Source: Cancercompass News: Breast Cancer - December 12, 2015 Category: Cancer & Oncology Source Type: news

AI vs Tamoxifen for DCIS? A Toss-up, Unless…AI vs Tamoxifen for DCIS? A Toss-up, Unless…
Both anastrozole and tamoxifen were effective at preventing recurrence of breast cancer in postmenopausal women with ductal carcinoma in situ. Age, toxicities should drive choice, say investigators. Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - December 11, 2015 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Anastrozole is as effective as current breast cancer drugs with fewer side effects
Post-menopausal women taking anastrozole experienced fewer womb, ovarian and skin cancers and fewer gynaecological symptoms, according to a study led by Queen Mary University. (Source: the Mail online | Health)
Source: the Mail online | Health - December 11, 2015 Category: Consumer Health News Source Type: news

For women taking 2 leading breast cancer drugs, symptoms tend to vary by patient’s age
UCLA Jonsson Comprehensive Cancer Center Dr. Patricia Ganz A study of two leading breast cancer drugs has determined that the breast cancer symptoms women experience while taking those drugs — and the severity of those symptoms — tend to vary based on the patients’ ages. The findings could be an important step toward personalized medicine for women with breast cancer, said Dr. Patricia Ganz, director of the UCLA Jonsson Comprehensive Cancer Center’s Prevention and Control Research program and the study’s first author. The study examined data for 1,193 postmenopausal women with a type of breast cancer called duct...
Source: UCLA Newsroom: Health Sciences - December 11, 2015 Category: Universities & Medical Training Source Type: news

Drug provides another treatment option for an early form of breast cancer
The drug anastrozole is effective in treating an early form of breast cancer, according to a clinical trial. The results of the trial show that anastrozole is as effective as tamoxifen for this type of breast cancer and could offer a new treatment option for post-menopausal women. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - December 11, 2015 Category: Science Source Type: news

Two Drugs Equal in Preventing Early Breast Cancer’s Return: Study
Women with ductal carcinoma in situ had similar outcomes with tamoxifen, anastrozole (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - December 11, 2015 Category: Cancer & Oncology Authors: webmaster at doctorslounge.com Tags: Oncology, Pharmacy, News, Source Type: news

Two Drugs Equal in Preventing Early Breast Cancer's Return: Study
Women with ductal carcinoma in situ had similar outcomes with tamoxifen, anastrozole (Source: WebMD Health)
Source: WebMD Health - December 11, 2015 Category: Consumer Health News Source Type: news

Drug provides another treatment option for an early form of breast cancer
(Queen Mary, University of London) The drug anastrozole is effective in treating an early form of breast cancer, according to a clinical trial led by Queen Mary University of London. The results of the IBIS-II DCIS trial show that anastrozole is as effective as tamoxifen for this type of breast cancer and could offer a new treatment option for post-menopausal women. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - December 11, 2015 Category: Cancer & Oncology Source Type: news